Genetic testing for peripheral neuropathy: we are entering a new era.

There are literally hundreds of different causes for peripheral neuropathy. While in most cases a decent history and a few blood tests can provide a potential cause, which often turns out be metabolic in nature (e.g diabetes, impaired glucose tolerance), in some patients a diagnosis proves elusive despite extensive investigations. This is a major problem […]

Read More…

Expanding the antibody spectrum of limbic encephalitis!

Limbic encephalitis (LE) mat have an underlying autoimmune etiologiy.  over the last decade numerous antibodies have emerged as potenital causative agents, and the antibodies have been directed against external epitopes of specific receptors.  In an upcoming issue of JNNP, Onugoren and colleagues reaffirm the association between GABAB and AMPR receptor antibodies and LE.  Importantly neoplastic […]

Read More…

Cholinesterase inhibitors in Parkinsons disease?

Cholinesterase inhibitors (ChIs) improve cholinergic transmission and thereby may lead to improved cognitive function in PD, although the risk of side-effects such as falls may be potentially increased.  In an upcoming issue of JNNP (On line first)  Pagano and colleagues conducted a meta-analysis to further assess these issues.  The results show a clear improvement of […]

Read More…

IVIg versus methylprednisone in CIDP: The treatment dilemmas!

The long-term treatment of CIDP is a vexing one often mired in lack of data from randomized controlled trials.  The ICE study suggested that a maintenance IVIg dose of 1g/kg every 3 weeks is associated with good therapeutic outcome.  Subsequent studies have suggested that steroids may lead to remission in a greater proportion of patients, […]

Read More…